Investigators often reference primary literature on platforms such as PubMed when designing protocols, and consult repositories at the NCBI and the FDA for context on analytical and regulatory standards
However, dosage, frequency, and method must be carefully controlled
[5] Peptides such as AOD 9604 and retatrutide, when sold with implied therapeutic claims (e.g., fat loss, metabolic enhancement), may legally constitute unlicensed medicinal products, regardless of how they are labelled by suppliers
Future GLP-2 trials in IBD should stratify patients by disease phenotype (mucosal UC, inflammatory CD, stricturing CD) and incorporate serial cross-sectional imaging to monitor for stricture progression, given the mechanistic link between GLP-2R signaling through subepithelial myofibroblasts and intestinal fibrogenesis
[45]R.F
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus